Effect of zinc supplementation on triglyceride, cholesterol, LDL, and HDL levels in zinc-deficient hemodialysis patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The purpose of this research was to study the effects of zinc supplementation on the concentration of serum zinc, total cholesterol, triglyceride, and cholesterol fractions (HDL, LDL) in HD patients.

Why It Was Studied

Zinc deficiency is known to occur in widely diverse areas of world.

It has now been recognized in many disease states, such as ESRD patients on maintenance hemodialysis (HD).

Who Took Part

PubMed indexes the participants as middle-aged adults.

In a double blind trial, the effects of oral zinc supplementation on the serum concentration of zinc, total cholesterol, HDL and LDL cholesterol, and triglyceride in HD patients were evaluated.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

What Was Measured

PubMed files the paper under topics including Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Deficiency Diseases, Dietary Supplements, Kidney Failure, Chronic and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Renal failure), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.